302 related articles for article (PubMed ID: 25612675)
1. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Estécio MR; Maddipoti S; Bueso-Ramos C; DiNardo CD; Yang H; Wei Y; Kondo K; Fang Z; Stevenson W; Chang KS; Pierce SA; Bohannan Z; Borthakur G; Kantarjian H; Garcia-Manero G
Br J Haematol; 2015 May; 169(3):344-51. PubMed ID: 25612675
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer.
Chen W; Gao N; Shen Y; Cen JN
J Gastroenterol Hepatol; 2010 Apr; 25(4):823-31. PubMed ID: 20492341
[TBL] [Abstract][Full Text] [Related]
3. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia.
Cheng CK; Li L; Cheng SH; Lau KM; Chan NP; Wong RS; Shing MM; Li CK; Ng MH
Blood; 2008 Oct; 112(8):3391-402. PubMed ID: 18663147
[TBL] [Abstract][Full Text] [Related]
5. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.
Lau QC; Raja E; Salto-Tellez M; Liu Q; Ito K; Inoue M; Putti TC; Loh M; Ko TK; Huang C; Bhalla KN; Zhu T; Ito Y; Sukumar S
Cancer Res; 2006 Jul; 66(13):6512-20. PubMed ID: 16818622
[TBL] [Abstract][Full Text] [Related]
6. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M
Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045
[TBL] [Abstract][Full Text] [Related]
7. [Significance of DNA methylation status of runx3 gene promoter region in acute leukemia].
Lin DJ; Fan RF; Liu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):263-6. PubMed ID: 18426645
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
[TBL] [Abstract][Full Text] [Related]
9. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
10. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
Zhang S; Wei L; Zhang A; Zhang L; Yu H
OMICS; 2009 Aug; 13(4):307-11. PubMed ID: 19645591
[TBL] [Abstract][Full Text] [Related]
11. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.
Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Ito Y; Chayama K; Yasui W
Pathobiology; 2004; 71(3):137-43. PubMed ID: 15051926
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
Goel A; Arnold CN; Tassone P; Chang DK; Niedzwiecki D; Dowell JM; Wasserman L; Compton C; Mayer RJ; Bertagnolli MM; Boland CR
Int J Cancer; 2004 Dec; 112(5):754-9. PubMed ID: 15386381
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between the methylation status of Runx3 gene and positive expression of estrogen receptor in breast cancer].
Yan Z; Gao S; Wu X; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):240-4. PubMed ID: 25975905
[TBL] [Abstract][Full Text] [Related]
15. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L
Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131
[TBL] [Abstract][Full Text] [Related]
16. Loss of RUNX3 is significantly associated with advanced tumor grade and stage in endometrial cancers.
Jeong D; Kim H; Ryu A; Sunwoo J; Choi SD; Nam GH; Jeon S
Mol Med Rep; 2018 Jun; 17(6):8173-8179. PubMed ID: 29693143
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of the promoter region of the human frizzled 9 gene in acute myeloid leukemia.
Zhang Y; Jiang Q; Kong X; Yang L; Hu W; Lv C; Li Y
Mol Med Rep; 2016 Aug; 14(2):1339-44. PubMed ID: 27314612
[TBL] [Abstract][Full Text] [Related]
19. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
